Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MindWalk HoldingsHYFT 33 Buyback Yield % is -0.98 as of Jul. 15, 2026. GuruFocus rates HYFT with a GF Score™ of 33/100 and a GF Value™ of $0.61 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 741 Biotechnology companies, MindWalk Holdings ranks better than 72.47% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for MindWalk Holdings's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HYFT vs ANVS, GANX, EXOZ: Buyback Yield % Comparison
For the Biotechnology subindustry, MindWalk Holdings's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MindWalk Holdings Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MindWalk Holdings's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where MindWalk Holdings's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MindWalk Holdings (HYFT) has a Buyback Yield % of -0.98 as of Jul. 15, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on MindWalk Holdings and its competitors. According to the industry distribution chart, MindWalk Holdings ranks #204 out of 741 companies in the Biotechnology industry, placing it in the top 27.5%.
Is MindWalk Holdings' Buyback Yield % too high?
MindWalk Holdings' current Buyback Yield % is -0.98. Based on the distribution chart, MindWalk Holdings ranks #204 out of 741 companies in the Biotechnology industry, which is above the industry midpoint. Overall, MindWalk Holdings has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does MindWalk Holdings' Buyback Yield % compare to ANVS and GANX?
According to the Biotechnology industry distribution chart, MindWalk Holdings ranks #204 out of 741 companies for Buyback Yield %. This puts MindWalk Holdings in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on MindWalk Holdings and its competitors. MindWalk Holdings's current Buyback Yield % is -0.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MindWalk Holdings stock overvalued right now?
Based on GuruFocus' analysis, MindWalk Holdings (HYFT) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.61, compared to a current price of $1.49 — trading 144.3% above its estimated fair value. The current Buyback Yield % is -0.98. MindWalk Holdings' overall GF Score™ is 33/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For MindWalk Holdings (HYFT), the current Buyback Yield % is -0.98 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MindWalk Holdings (HYFT) Overvalued in 2026?
Based on GuruFocus' analysis, MindWalk Holdings stock appears to be overvalued.
The current stock price of $1.49 is trading 144.3% above its estimated GF Value™ of $0.61.
GuruFocus considers MindWalk Holdings to be Significantly Overvalued.
Key valuation signals for HYFT:
Buyback Yield %: -0.98
GF Value™: $0.61 vs. price of $1.49 (144.3% above fair value)
No single metric tells the full story. See the HYFT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MindWalk Holdings Corp is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, MindWalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.
33GF Score
Get the complete analysis for HYFT
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HYFT has been successfully added to your 
